Companies / BOC Sciences / Cixutumumab
BOC Sciences

Cixutumumab | BOC Sciences

Cixutumumab is a humanized anti-IGF-1R monoclonal antibody for the treatment of solid tumors. Cixutumumab selectively binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More